Autism spectrum disorder care reference (2026)

ASD care in 2026 organises around a multidisciplinary approach.

Behavioural and educational therapy: applied behaviour analysis (ABA) is the most-evidenced behavioural intervention, particularly when started early. Speech and language therapy, occupational therapy, social skills training, and structured educational support are core components. Family support and parent training are integral.

Pharmacotherapy for associated symptoms.

Irritability and aggression: risperidone and aripiprazole are FDA-approved for ASD-associated irritability and aggression. They are used when behavioural intervention alone is insufficient.

ADHD-like symptoms: stimulants (methylphenidate, amphetamines) and non-stimulants (atomoxetine, guanfacine) are used in selected patients with attention and hyperactivity symptoms.

Anxiety and depression: SSRIs and other standard antidepressants are used when these comorbidities are present.

Sleep: melatonin is widely used for sleep-onset issues common in ASD.

Emerging tier: mechanism-targeted programs for ASD core symptoms (vasopressin pathway, oxytocin pathway, GABA pathway, AMPA receptor modulators, others) are in late-stage trials. None has yet been approved specifically for core ASD symptoms.

The care-pathway question matters. Early identification through structured developmental screening, access to specialty diagnostic evaluation, and integrated multidisciplinary care models are the addressable-population enablers. Disparities in access (geographic, socioeconomic, racial) remain substantial.